Results 201 to 210 of about 53,085 (229)

Once-per-Week Selinexor, Bortezomib, and Dexamethasone Versus Twice-per-Week Bortezomib and Dexamethasone in Patients With Multiple Myeloma (BOSTON): A Randomised, Open-Label, Phase 3 Trial

Lancet, The, 2020
Roman Hajek, Thierry Facon, Athanasios Dimopoulos   +2 more
exaly  

BORTEZOMIB COMPOSITIONS

2023
SUNDARAM SRIKANTH, STEWART DANIEL CHARLES   +1 more
openaire   +5 more sources

Bortezomib

Reactions Weekly, 2019
openaire   +2 more sources

Bortezomib

Reactions Weekly, 2022
openaire   +1 more source

Bortezomib

Reactions Weekly, 2015
  +4 more sources

Bortezomib, Doxorubicin and Dexamethasone in Advanced Multiple Myeloma

Annals of Oncology, 2008
Mario Boccadoro, Benedetto Bruno, Francesca Gay   +2 more
exaly  

Bortezomib (VELCADE®) in Metastatic Breast Cancer: Pharmacodynamics, Biological Effects, and Prediction of Clinical Benefits

Annals of Oncology, 2006
A M Gonzalez-Angulo, C H Yang, C H Yang
exaly  

Panorama 2: Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed and Bortezomib-Refractory Myeloma

Blood, 2013
Paul G. Richardson, Sagar Lonial, Donna M Weber   +2 more
exaly  

A Phase II Study of Bortezomib in Mantle Cell Lymphoma: The National Cancer Institute of Canada Clinical Trials Group Trial IND.150

Annals of Oncology, 2007
Randy D Gascoyne, Elizabeth A Eisenhauer, R Klasa   +2 more
exaly  

Home Administration of Bortezomib in Multiple Myeloma Is Cost-Effective and Is Preferred by Patients Compared With Hospital Administration: Results of a Prospective Single-Center Study

Annals of Oncology, 2016
V Dubruille, N Blin, Béatrice Mahé
exaly